Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Can PSA nadir predict prognosis in men receiving hormonal therapy for prostate cancer after primary treatment failure?

Nature Clinical Practice Urology volume 3, pages 252–253 (2006)Cite this article

boxed-textStewart AJ et al. (2005) Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure. J Clin Oncol 23: 6556–6560

Men who have failed radical therapy and have adverse PSA indices (rapid doubling time and/or PSA nadir of >0.2 ng/ml) represent a high-risk subcohort of patients, and should be considered for trials of novel treatments

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Thompson IM et al. (2004) Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med 350: 2239–2246

    Article  CAS  Google Scholar 

  2. D'Amico AV et al. (2003) Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 95: 1376–1383

    Article  Google Scholar 

  3. Kwak C et al. (2002) Prognostic significance of the nadir prostate specific antigen level after hormone therapy for prostate cancer. J Urol 168: 995–1000

    Article  Google Scholar 

  4. Pound CR et al. (1999) Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281: 1591–1597

    Article  CAS  Google Scholar 

  5. Lee AK and D'Amico AV (2005) Utility of prostate-specific antigen kinetics in addition to clinical factors in the selection of patients for salvage local therapy. J Clin Oncol 23: 8192–8197

    Article  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Sandra Ford, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Associate Professor at the University of Toronto, and the Chief of Urology at the University Health Network, Toronto, ON, Canada

    Neil Fleshner

Authors
  1. Neil Fleshner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Neil Fleshner.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fleshner, N. Can PSA nadir predict prognosis in men receiving hormonal therapy for prostate cancer after primary treatment failure?. Nat Rev Urol 3, 252–253 (2006). https://doi.org/10.1038/ncpuro0460

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpuro0460

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing